Compositions of Polypeptides for Subunit Vaccines for SARS-CoV-2
Invention type: Technology
/
Case number: #22703
The present disclosure relates to, inter alia, variants of the receptor binding domain of a coronavirus (e.g., SARS-CoV-2) having increased immunogenicity and reduced aggregation, and the use of the RBD variants in methods for preventing infection of the coronavirus.
Researchers
J. Christopher Love
/
Neil Dalvie
/
Sergio Rodriguez
Departments: Department of Chemical Engineering
Technology Areas: Therapeutics: Proteins & Antibodies, Vaccines
Impact Areas: Healthy Living
-
novel sars-cov-2 antigens and uses thereof
United States of America | Granted | 11,872,279
License this technology
Interested in this technology? Connect with our experienced licensing team to initiate the process.
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.